CDC has kicked off the SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology and Surveillance (SPHERES) consortium, which will greatly expand the use of whole genome sequencing (WGS) of the COVID-19 virus.
This national network of sequencing laboratories will speed the release of SARS-CoV-2 sequence data into the public domain.
SPHERES will provide consistent, real-time sequence data to the public health response teams investigating cases and clusters of COVID-19 across the country. It will help them better understand how the virus is spreading, both nationally and in their local communities. Better data, in turn, will help public health officials interrupt chains of transmission, prevent new cases of illness, and protect and save lives.
“The U.S. is the world’s leader in advanced rapid genome sequencing. This coordinated effort across our public, private, clinical, and academic public health laboratories will play a vital role in understanding the transmission, evolution, and treatment of SARS-CoV-2. I am confident that our finest, most skilled minds are working together to help us save lives today and tomorrow,” said CDC Director Robert Redfield, M.D.
Tracking the COVID-19 virus as it evolves
Genomic sequence data can give unprecedented insight into the biology of SARS-CoV-2, the virus that causes COVID-19, and help define the changing landscape of the pandemic. By sequencing viruses from across the United States, CDC and other public health authorities can monitor important changes in the virus and use this information to guide contact tracing, public health mitigation efforts, and infection control strategies.
The SPHERES consortium is an ambitious effort to coordinate SARS-CoV-2 genome sequencing nationally, organizing dozens of smaller, individual efforts into a single, distributed network of laboratories, institutions and corporations. The consortium combines the expertise, technology, and resources of 40 state and local public health departments, several large clinical laboratories, and over two dozen collaborating institutions across the federal government, academia, and the private sector.
SPHERES will establish best practices and consensus data standards, accelerate open data sharing, and establish a pool of resources and expertise to help bring cutting-edge technology to the national COVID-19 response.
SPHERES data open, shared
Consortium members share a commitment to rapid open sequence sharing. They plan to submit all useful sequence data into public repositories at the National Library of Medicine’s National Center for Biotechnology Information (NLM/NCBI), the Global Initiative on Sharing Avian Influenza Data (GISAID), and other public sequence repositories. This will help ensure that that viral sequence data from across the United States is rapidly available for public health decision making and freely accessible to researchers everywhere.
Consortium members include:
Federal agencies and laboratories
Centers for Disease Control and Prevention, Office of Advanced Molecular Detections
Argonne National Laboratory
National Institute of Allergy and Infectious Diseases, Office of Genomics and Advanced Technology
National Institute of Standards and Technology
National Library of Medicine’s National Center for Biotechnology Information
Walter Reed Army Institute of Research
State/local public health laboratories
Arizona
California
Delaware
District of Columbia
Florida
Hawaii
Massachusetts
Maine
Maryland
Michigan
Minnesota
North Carolina
New Mexico
North Dakota
Nevada
New York
Utah
Virginia
Washington
Wisconsin
Wyoming
Academic Institutions
Baylor University
Cornell University
Fred Hutchinson Cancer Research Center
Mount Sinai School of Medicine
New York University
Northern Arizona University
University of Buffalo
University of California, Berkeley
University of California, Davis
University of California, Irvine
University of California, Los Angeles
University of California, San Francisco
University of California, Santa Cruz
University of Chicago
University of Maryland
University of Minnesota
University of Nebraska
University of New Mexico
University of Washington
Yale University
Corporations*
Abbott Diagnostics
bioMérieux
Color Genomics
Gingko Bioworks
IDbyDNA
Illumina
In-Q-Tel
LabCorp
One Codex
Oxford Nanopore Technologies
Pacific Biosciences
Qiagen
Quest Diagnostics
Verily Life Sciences
*Names of corporations are provided for information purposes only, and their inclusion here does not constitute an endorsement of the corporations or any of their commercial products or services by the U.S. Centers for Disease Control and Prevention.
Non-profit public health or research institutes
Association of Public Health Laboratories
Bill and Melinda Gates Foundation
Broad Institute
Chan Zuckerberg BioHub
J. Craig Venter Institute
Public Health Alliance for Genomic Epidemiology
Scripps Research
The Jackson Laboratory
Translational Genomics Research Institute – North
Walder Foundation
For the past six years, CDC’s Office of Advanced Molecular Detection program has invested in federal and state public health laboratories to expand the use of pathogen genomics and other advanced laboratory technologies for infectious disease surveillance and outbreak response. The current consortium investment aims to save lives in the SARS-CoV-2 pandemic and prepare the United States and the world for future pandemic response.
To learn more about genomic sequencing or CDC’s work in advanced molecular detection, visit https://www.cdc.gov/amd/
